Abeona Therapeutics
ABEO
75 hedge funds and large institutions have $58.2M invested in Abeona Therapeutics in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 20 reducing their positions, and 13 closing their positions.
50% more call options, than puts
Call options by funds: $556K | Put options by funds: $371K
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
14% more capital invested
Capital invested by funds: $50.8M → $58.2M (+$7.33M)
10% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 20
3% more funds holding
Funds holding: 73 → 75 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.06% less ownership
Funds ownership: 1.32% → 1.26% (-0.06%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$2.78M |
| 2 |
BlackRock
New York
|
+$1.96M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.77M |
| 4 |
Morgan Stanley
New York
|
+$769K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$697K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.94M |
| 2 |
Renaissance Technologies
New York
|
-$1.76M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.52M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$619K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$404K |
ABEO Hedge Fund Activity: Q1 2021 in Review
75 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q1 2021, worth a combined $58.2M — up 14% from $50.8M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ABEO positions and 13 closed out — a net gain of 3 holders — while 22 added to existing stakes and 20 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $2.78M. The largest seller was Citadel Advisors, cutting an estimated $5.94M.
- 75 institutional investors held Abeona Therapeutics (ABEO) as of Q1 2021, up from 73 in Q4 2020.
- Funds reported $58.2M of Abeona Therapeutics stock for Q1 2021, up 14% quarter-over-quarter.
- 16 funds opened new Abeona Therapeutics positions in Q1 2021 and 13 closed out, a net change of +3 holders.
- The largest Abeona Therapeutics buyer in Q1 2021 was JP Morgan Chase, an estimated $2.78M added.
- The largest Abeona Therapeutics seller in Q1 2021 was Citadel Advisors, an estimated $5.94M sold.
Based on aggregated 13F filings for Q1 2021.